Список проголосовавших за комментарий " Sector Summary: The Healthcare sector (-0.37%) is trading lower today, in-line w/ the S&P 500 (-0.26%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Biocept (<strong>BIOC</strong> +9.93%) Awarded Patent in Australia for the Use of Antibodies in Microchannels to Capture Circulating Tumor Cells and Other Rare Cells</li><li>ViewRay (<strong>VRAY</strong> +13.99%) raised aggregate gross proceeds of approximately $26.1 million through a private placement of its common stock and warrants</li><li>Catabasis Pharma (<strong>CATB</strong> +12.77%) announces the publication of Phase 1 data on Edasalonexent in adult subjects in the Journal of Clinical Pharmacology; data demonstrates that edasalonexent was safe, well tolerated, and inhibited activated NF-kB in adult</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Amedica (<strong>AMDA</strong> -31.6%) prices public offering of common stock/warrants at $0.51 for one share of common stock and 0.45 warrants for gross proceeds of approx $4.5 mln</li><li>Zynerba Pharma (<strong>ZYNE</strong> -14.56%) prices underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share for proceeds of about $50.4 mln</li><li>Can-Fite Biopharma (<strong>CANF</strong> -6.22%) announces $5 mln registered direct offering at $2.00/share</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Mallinckrodt plc (<strong>MNK</strong> +3.93%) Expect MNK to recover post-company update; Buy, $85 tgt — Mizuho</li><li>BioLife Solutions (<strong>BLFS</strong> +1.75%) initiated with a Buy at Maxim Group; tgt $3</li><li>Transenterix (<strong>TRXC</strong> -1.37%) downgraded to Mkt Perform from Outperform at Raymond James</li><li>Covanta (<strong>CVA</strong> -3.36%) downgraded to Equal Weight from Overweight at Barclays</li><li>Cerner (<strong>CERN</strong> -1.22%) downgraded to Equal Weight from Overweight at Barclays</li></ul>"